Posted on January 22nd, 2015 by
Myeloproliferative neoplasms (MPN) are a related group of blood cancers. In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. The three main types of MPN are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In addition to developing on its own, myelofibrosis may also develop as a result of ET or PMF.
Myeloproliferative neoplasms are most common in older adults. Out of every 100,000 people in the United States, an estimated 44 to 57 people have PV, and a similar number have ET. Myelofibrosis is less common, affecting 4 to 6 people per 100,000.
An important advance in our understanding of MPN is the identification of certain gene mutations that contribute to these conditions. In the case of myelofibrosis, this discovery has contributed to the development of new drugs to treat the condition. The last year marked important progress in the management of PV and myelofibrosis with a new treatment option now available for PV patients.
CancerConnect News coverage of advances in the management of MPNs included the following key developments:
2014 Ask the MPN Expert
2014 Research and FDA News in Polycythemia Vera
2014 Research News in Myelofibrosis
2014 Research News in Essential Thrombocythemia
Stay up to date on MPN research news and connect with others affected by polycythemia vera, myelofiboriss and essential thrombocythemia in the CancerConnect online MPN community here.
Copyright © 2015 CancerConsultants. All Rights Reserved.
You must be logged-in to the site to post a comment.